CN102770141A - 含有左氧氟沙星或其盐、或者它们的溶剂合物的眼感染症治疗用滴眼剂，眼感染症的治疗方法，左氧氟沙星或其盐、或者它们的溶剂合物及其使用 - Google Patents

含有左氧氟沙星或其盐、或者它们的溶剂合物的眼感染症治疗用滴眼剂，眼感染症的治疗方法，左氧氟沙星或其盐、或者它们的溶剂合物及其使用 Download PDF

Info

Publication number
CN102770141A
CN102770141A CN2010800646540A CN201080064654A CN102770141A CN 102770141 A CN102770141 A CN 102770141A CN 2010800646540 A CN2010800646540 A CN 2010800646540A CN 201080064654 A CN201080064654 A CN 201080064654A CN 102770141 A CN102770141 A CN 102770141A
Authority
CN
China
Prior art keywords
levofloxacin
genus
eye
staphylococcus
conjunctivitis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2010800646540A
Other languages
English (en)
Chinese (zh)
Inventor
长野敬
阪中浩二
中村雅胤
河津刚一
伊吹肇
坂本佳代子
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sankyo Co Ltd
Santen Pharmaceutical Co Ltd
Original Assignee
Sankyo Co Ltd
Santen Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Co Ltd, Santen Pharmaceutical Co Ltd filed Critical Sankyo Co Ltd
Publication of CN102770141A publication Critical patent/CN102770141A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CN2010800646540A 2010-02-25 2010-12-16 含有左氧氟沙星或其盐、或者它们的溶剂合物的眼感染症治疗用滴眼剂，眼感染症的治疗方法，左氧氟沙星或其盐、或者它们的溶剂合物及其使用 Pending CN102770141A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2010040281 2010-02-25
JP2010-040281 2010-02-25
PCT/JP2010/072685 WO2011104981A1 (ja) 2010-02-25 2010-12-16 レボフロキサシンもしくはその塩またはそれらの溶媒和物を含有する眼感染症治療用点眼剤、眼感染症の治療方法、レボフロキサシンもしくはその塩またはそれらの溶媒和物、ならびにその使用

Publications (1)

Publication Number Publication Date
CN102770141A true CN102770141A (zh) 2012-11-07

Family

ID=44506417

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2010800646540A Pending CN102770141A (zh) 2010-02-25 2010-12-16 含有左氧氟沙星或其盐、或者它们的溶剂合物的眼感染症治疗用滴眼剂，眼感染症的治疗方法，左氧氟沙星或其盐、或者它们的溶剂合物及其使用

Country Status (16)

Country Link
US (1) US20120316158A1 (https=)
EP (1) EP2540299B1 (https=)
JP (3) JP5600056B2 (https=)
KR (2) KR20130043611A (https=)
CN (1) CN102770141A (https=)
BR (1) BR112012021247A2 (https=)
CA (1) CA2791190C (https=)
EA (1) EA201290827A1 (https=)
ES (1) ES2568647T3 (https=)
MX (1) MX349603B (https=)
MY (1) MY183483A (https=)
NZ (1) NZ602126A (https=)
PH (2) PH12016501747B1 (https=)
SG (1) SG183427A1 (https=)
TW (1) TWI488627B (https=)
WO (1) WO2011104981A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106138062A (zh) * 2015-01-09 2016-11-23 周元铎 盐酸左氧氟沙星在制备蚕药中的应用
CN113677327A (zh) * 2019-04-05 2021-11-19 Ntc有限公司 耳科组合物

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12016501747B1 (en) * 2010-02-25 2022-06-22 Daiichi Sankyo Co Ltd Ophthalmic solution for treating ocular infection comprising levofloxacin or salt thereof or solvate of the same, method for treating ocular infection, levofloxacin or salt thereof or solvate of the same, and the use thereof
CN103550144B (zh) * 2013-10-25 2015-10-14 深圳朗欧医药集团有限公司 盐酸左氧氟沙星组合物注射液及其制备方法
JP6363833B2 (ja) * 2013-11-22 2018-07-25 ナノシータ株式会社 薄膜状高分子構造体

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005000307A1 (en) * 2003-06-26 2005-01-06 Santen Pharmaceutical Co., Ltd. Ophthalmic composition containing quinolones and method of use

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3038722B2 (ja) 1989-06-23 2000-05-08 日本電気株式会社 接合型電界効果トランジスタ
JP3192290B2 (ja) 1993-08-04 2001-07-23 カネボウ株式会社 ポリエステル製耐熱ボトル
WO2003028664A2 (en) * 2001-10-03 2003-04-10 Teva Pharmaceutical Industries Ltd. Preparation of levofloxacin and forms thereof
EP1458391B1 (en) * 2001-11-30 2007-09-05 LG Life Sciences Ltd. A method of treating bacterial infections using gemifloxacin or a salt thereof and a beta-lactam antibiotic
US20050009836A1 (en) 2003-06-26 2005-01-13 Laskar Paul A. Ophthalmic composition containing quinolones and method of use
ES2671342T3 (es) * 2006-02-10 2018-06-06 Pari Pharma Gmbh Antibióticos nebulizados para terapia de inhalación
WO2008005276A2 (en) * 2006-06-30 2008-01-10 Directcontact Llc Growth factor delivery system containing antimicrobial agents
EP2143422A1 (en) * 2008-07-11 2010-01-13 S.I.F.I - Società Industria Farmaceutica Italiana - S.P.A. Ophthalmic compositions containing gemifloxacin for the treatment of ocular infections
PH12016501747B1 (en) * 2010-02-25 2022-06-22 Daiichi Sankyo Co Ltd Ophthalmic solution for treating ocular infection comprising levofloxacin or salt thereof or solvate of the same, method for treating ocular infection, levofloxacin or salt thereof or solvate of the same, and the use thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005000307A1 (en) * 2003-06-26 2005-01-06 Santen Pharmaceutical Co., Ltd. Ophthalmic composition containing quinolones and method of use

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106138062A (zh) * 2015-01-09 2016-11-23 周元铎 盐酸左氧氟沙星在制备蚕药中的应用
CN113677327A (zh) * 2019-04-05 2021-11-19 Ntc有限公司 耳科组合物

Also Published As

Publication number Publication date
SG183427A1 (en) 2012-09-27
NZ602126A (en) 2013-10-25
WO2011104981A1 (ja) 2011-09-01
JP5600056B2 (ja) 2014-10-01
MX2012009844A (es) 2012-09-21
PH12016501747A1 (en) 2019-02-11
JP2013241464A (ja) 2013-12-05
KR20130043611A (ko) 2013-04-30
JP5674882B2 (ja) 2015-02-25
EA201290827A1 (ru) 2013-03-29
EP2540299A4 (en) 2013-07-24
BR112012021247A2 (pt) 2018-04-03
AU2010346703A1 (en) 2012-09-20
ES2568647T3 (es) 2016-05-03
TWI488627B (zh) 2015-06-21
CA2791190C (en) 2017-12-12
KR20170070265A (ko) 2017-06-21
JP2011195564A (ja) 2011-10-06
PH12012501674A1 (en) 2012-11-05
PH12016501747B1 (en) 2022-06-22
US20120316158A1 (en) 2012-12-13
EP2540299A1 (en) 2013-01-02
EP2540299B1 (en) 2016-04-13
CA2791190A1 (en) 2011-09-01
MX349603B (es) 2017-08-03
MY183483A (en) 2021-02-20
TW201129364A (en) 2011-09-01
JP2012162532A (ja) 2012-08-30
HK1177887A1 (en) 2013-08-30

Similar Documents

Publication Publication Date Title
US20110294768A1 (en) Ophthalmic Suspension for Ocular Use
TW201717973A (zh) 無刺激性眼用聚乙烯吡咯啶酮-碘組成物
CA2727605A1 (en) Povidone iodine, a novel alternative preservative for ophthalmic compositions
CN102770141A (zh) 含有左氧氟沙星或其盐、或者它们的溶剂合物的眼感染症治疗用滴眼剂，眼感染症的治疗方法，左氧氟沙星或其盐、或者它们的溶剂合物及其使用
WO2016072440A1 (ja) 眼科用水性組成物
Tabbara et al. Treatment of acute bacterial conjunctivitis with topical lomefloxacin 0.3% compared to topical ofloxacin 0.3%
CN107875119B (zh) 一种富马酸依美斯汀水性药物组合物及其制备方法
CN109846820B (zh) 一种氧氟沙星滴眼液及其制备方法
WO2016196989A1 (en) Topical composition
Storey et al. Endophthalmitis following intravitreal injection
HK1178045A (en) Eye drops for treating eye infection containing levofloxacin, salt thereof or solvate of same, method for treating eye infection, levofloxacin, salt thereof or solvate of same, and utilization thereof
CN114129590B (zh) 一种眼用组合物及其制备方法与应用
US11672798B2 (en) Ciprofloxacin ophthalmic topical composition for treating ocular disease
Tabbara et al. Effects of fusidic acid on staphylococcal keratitis.
HK1177887B (en) Eye drops for treating eye infection containing levofloxacin, salt thereof or solvate of same, method for treating eye infection, levofloxacin, salt thereof or solvate of same, and utilization thereof
Adamiec-Mroczek et al. Efficient antiseptic prophylaxis in the era of antibiotic resistance
EP4611762A1 (en) Novel ophthalmic composition
WO2025229666A1 (en) Novel ophthalmic gel composition
Khuu et al. Contact Lens-Related Corneal Ulcer: A Teaching Case Report.
Tiwari Pharmacological considerations in cataract surgery
JP2004049228A (ja) 麦粒腫の病態モデル動物およびその作製方法
HK1043739A1 (en) Use of a pharmaceutical composition in the manufacture of a medicament for the treatment of pathological conditions of the eye caused by bacteria, viruses, fungi, yeasts and protozoa

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1178045

Country of ref document: HK

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20121107